• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
188272 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  : g7 p2 ~  z8 d5 x0 `
& M( E* ~) A# F" Q1 |9 X

. h) e% B/ V  K1 \) k' MSub-category:! ^& p0 W- ?* N0 {6 K2 j) Z
Molecular Targets
( ^0 G$ c& ?, R
1 `6 W9 f+ g- P3 _+ O( R0 C9 E4 s% h: ?3 p( I8 K+ Z9 A8 U
Category:
% L$ b& M# @5 Y" f8 L8 tTumor Biology
) W5 a: H2 \' V; S. O* K: S, D
1 j  H7 D! D( W$ s: h4 v% s& u$ _% |8 h; H3 {
Meeting:7 R: P# f3 s& E$ v) {
2011 ASCO Annual Meeting 5 d( H" z# J2 h% a1 A7 I

) A& u# [% r- q( @: x% s, \% x7 E% n3 E5 o. a
Session Type and Session Title:
- j! |+ I) |* Z! i3 _" a3 tPoster Discussion Session, Tumor Biology
# Q& b1 a( @8 h2 F
6 B* O  J; c) ?) \$ U9 j/ m3 ?+ i4 ~/ }9 g1 P
Abstract No:  o. u; j2 I" J: o0 C, T
10517
6 J9 [+ I# R) K: A, ?7 P; T1 ]/ e# L5 f8 I; Z& [# R) E

! V+ V) a, M1 X4 L- ICitation:4 t4 o' {! A/ z: P
J Clin Oncol 29: 2011 (suppl; abstr 10517)
" X3 ]" C/ H; O) I0 }  N0 p/ e' w5 J
0 I" ^. I: Z! {# X! ^% J: l/ W) J6 o8 l  c
Author(s):, F" t' _/ M5 s. T5 C) Z0 A* ~* t
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ' D3 F% M) e* A& J2 B4 ?, P9 H

4 C! n4 y( i2 M6 O/ i& Q6 s7 g, R! x! U' |" U4 U  u

* T+ @. w, Q% K% ~+ F+ F- w: LAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.8 R% T" G4 z  N- f. n

& C# ?2 p5 W% X. _Abstract Disclosures
- y7 L& ?! m9 E4 T! N$ f4 c1 a7 }) s" ^$ j( R% Q$ ]
Abstract:
) ^) \# F0 n& y2 ^4 M" Z9 C* O; [- `% j0 D# ]: M
; ^3 }5 J( t( @5 g1 J3 B
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 S8 j) A+ D1 \" H1 }$ f. S$ u: i" [7 i- E

4 X; Z" ?+ s8 R# N2 J, O
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 * I- c. W% V7 R1 y+ _$ x
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
3 }" b! f( ^: s4 b1 P2 ~3 l
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
0 H# j) w, U/ ^) `) E9 d% i易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。! c  N$ r/ X% I) S* {. i/ w( D* ~
ALK一个指标医院要900多 ...
# j, V, z6 g$ J. `8 M
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?+ y" ?7 h( P) V) H0 @, N

2 s9 v+ x/ h( h现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表